MedTrace Logo

Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects

NCT04173962 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-05-10

Study results available
· View outcomes & findings →

Summary

The objective of this study is to examine the effect of a single IV dose of ketamine (0.5 mg/kg) on laboratory-induced stress in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Ketamine

administered 1 week prior to a laboratory-induced stress

DRUG

Midazolam

administered 1 week prior to a laboratory-induced stress

Sponsors & Collaborators

Principal Investigators

  • James Murrough, MD, PhD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-08
Primary Completion
2021-03-18
Completion
2021-03-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04173962 on ClinicalTrials.gov